VERA

Vera Therapeutics, Inc. (VERA) Management Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Leadership Execution

Management is operating with a very strong liquidity position, with a current ratio of 10.9x and cash per share of 6.95.

Execution remains challenged by negative profitability and cash generation, with ROE at -84.1% and free cash flow per share at -4.72.

Capital Allocation

The balance sheet remains conservative, with debt-to-equity at 0.18x and net debt to EBITDA near zero.

Capital allocation flexibility is supported by a cash ratio of 1.01x and working capital of 479.2M, but there is no evidence of durable earnings power yet.

Governance Incentives

No fresh news indicates a governance change or incentive reset this month.

The company still appears to be in a turnaround phase, so management credibility will depend on translating liquidity into sustained operating improvement.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →